CD8^+^ T cells recognize peptides in association with class I MHC proteins on the surface of cells. In general, these MHC class I--associated peptides are derived from intracellular proteins ([@B1]). In the classical pathway for processing of class I--associated peptides, cytosolic proteases such as the proteasome degrade proteins to generate peptides that are transported into the endoplasmic reticulum (ER)^1^ by the transporter associated with antigen processing (TAP; 2--6). Upon entry into the ER, the peptides are bound to "empty" or peptide-free MHC class I molecules that are associated with TAP ([@B7], [@B8]) via an intermediary protein, tapasin ([@B9]). After binding peptide, the MHC class I heterotrimer dissociates from TAP and proceeds through the ER, Golgi, and exocytic pathway to the cell surface ([@B10]). The peptides in association with the MHC class I molecule are then available for recognition on the cell surface by CTLs.

Because membrane and secreted proteins are normally cotranslationally translocated into the ER, they would appear to bypass the cytosolic proteases of the classical pathway. Nevertheless, a number of MHC class I--associated peptides that originate from membrane proteins have been identified, and the pathways by which they are produced have been the object of several recent studies. Peptides from the signal sequences of IP-30, HLA-E, Signal Sequence Receptor Protein--α (SSR-α), and calreticulin ([@B11], [@B12]), as well as peptides from more internal sequences of the HIV env ([@B13]) and Epstein-Barr virus Latent Membrane Protein 2 (LMP2) proteins ([@B14]), and a peptide epitope of uncertain location ([@B15]) are presented by HLA-A\*0201 in cells that lack expression of TAP. Independence of TAP indicates that the source proteins for these peptides are produced in the ER, and that complete proteolytic processing occurs in the ER or distal vesicular compartments, and not the cytosol. Although the signal peptidase is likely to be involved in the generation of signal sequence--derived peptides, it is unlikely to account for the production of peptides from more internal sequences. In addition, none of the peptides derived from signal sequences is full-length, raising the possibility that additional proteases are involved in secondary proteolytic events. In support of this possibility, it has been shown that the production of some, but not all, of these peptides is sensitive to high concentrations of the protease inhibitor LLnL ([@B16]). In addition, several vaccinia virus constructs containing peptide epitopes embedded in a larger sequence that is in turn linked to a signal sequence can be processed for presentation in a TAP-independent manner, presumably via ER resident proteases ([@B17]--[@B20]).

An alternative pathway for the processing of membrane protein--derived epitopes has been suggested by the observation that the presentation of peptides from the measles virus transmembrane ([@B21]) and the HIV env ([@B22]) proteins as well as peptides from the signal sequence of some MHC class I molecules ([@B23], [@B24]) and the LCMV gp33 protein ([@B25]) are dependent on TAP function. Roelse et al. ([@B26]) demonstrated that in vitro, peptides transported into the ER that are too long to bind to class I MHC molecules could be exported to the cytosol for further processing, and the products then retransported to the ER by TAP. Although a similar mechanism has not been demonstrated in vivo, partial proteolysis in the ER followed by final proteolysis in the cytosol could account for the TAP-dependent presentation of these epitopes. Alternatively, their presentation may occur after mistranslation of the source protein in the cytosol ([@B27]). This could occur either as the result of incomplete translational blockade by signal sequences on cytosolic ribosomes, or by the use of an alternate start codon internal to the signal sequence, as has been shown to occur for several class I--associated epitopes ([@B28]--[@B34]). Support for such a cytosolic mistranslation mechanism has been provided by observations with an HLA-B\*3501--restricted HIV env epitope. This epitope contains a site for N-linked glycosylation that is modified during cotranslational translocation of the full-length protein into the ER ([@B35]). However, the epitope presented by HLA-B\*3501 has not undergone either glycosylation or deglycosylation ([@B22], [@B36]). Thus, it appears that HIV env protein that gives rise to this epitope has been mistranslated in the cytosol and processed there.

A final possible explanation for the TAP-dependent presentation of peptides derived from membrane proteins is that the source protein itself is exported from the ER for proteolysis in the cytosol. Recently, the reverse translocation of several apparently full-length membrane proteins from the ER to the cytosol has been reported ([@B37]--[@B48]). Visualization of these proteins has generally been possible only after inhibition by protease inhibitors, in most cases those which are effective against the proteasome ([@B38]--[@B48]). However, no evidence supporting the involvement of this pathway in the production of MHC class I--associated peptide antigens has been presented. Thus, at this point in time, the only in vivo data available for the processing of membrane proteins for class I presentation support a cytosolic mistranslation mechanism.

Recently, we described an epitope from the membrane-associated protein tyrosinase that is presented by HLA-A\*0201 to CTL reactive with human melanomas ([@B49]). The sequence of this peptide, YM**[D]{.ul}**GTMSQV, differed from the corresponding primary sequence of the tyrosinase protein, YM**[N]{.ul}**GTMSQV, by the substitution of aspartic acid for asparagine at position 3. This was shown to be due to a posttranslational conversion, and neither to spontaneous deamidation nor RNA editing. The asparagine in YM**[N]{.ul}**GTMSQV is part of an N-linked glycosylation site and a mammalian enzyme, peptide-N^4^-(N acetyl-β-glucosaminyl) asparagine amidase (PNGase), has been isolated, which removes the N-linked oligosaccharide side chains from glycopeptides. This process converts the modified asparagine residues to aspartic acid ([@B50]). Our working hypothesis is that glycosylation in the ER and subsequent deglycosylation at an unknown site are responsible for the conversion of YM**[N]{.ul}**GTMSQV to YM**[D]{.ul}**GTMSQV. Regardless of whether this hypothesis is correct, it focused our attention on how tyrosinase is processed. Since tyrosinase is a melanosomal membrane protein, mistranslation of tyrosinase in the cytosol could lead to proteolysis of the unconverted protein, generating peptides that would be transported by TAP into the ER and converted before or after binding to HLA-A\*0201. Alternatively, conversion could occur during normal cotranslational translocation into the ER and subsequent degradation either in the ER, after export of partially proteolysed fragments, or in the cytosol after reverse translocation of the source protein. In this paper, we have examined the processing and conversion of this epitope in detail.

Materials and Methods {#MaterialsMethods}
=====================

Cell Lines.
-----------

NA8 Mel + Tyr was derived by transfection of the tyrosinase negative melanoma NA8 Mel with the full-length tyrosinase gene and was a gift from Vincent Brichard and Thierry Boon (Ludwig Institute for Cancer, Université Catholique de Louvain, Brussels, Belgium). NA8 Mel + T3.1 was derived from transfection of NA8 Mel with the truncated tyrosinase cDNA T3.1 ([@B51]). JY is a human HLA-A\*0201^+^ cell line. T2 is an HLA-A\*0201^+^ human B lymphoblastoid cell line with a deletion in the MHC including the genes for TAP1, TAP2, LMP2, and LMP7 ([@B52], [@B53]). All cell lines were maintained in RPMI 1640 supplemented with 5% FCS/SerXtend (Irvine Scientific, Santa Ana, CA) in a humidified 5% CO~2~ atmosphere at 37°C.

Peptides.
---------

Synthetic peptides were made by standard Fmoc chemistry using a model AMS422 peptide synthesizer (Gilson Co. Inc., Middleton, WI). All peptides were purified to \>98% purity by reverse-phase HPLC on a C-8 column (VYDAC, Hesperia, CA). Purity and identity were established using a triple quadropole mass spectrometer (model TSQ-7000; Finnigan, San Jose, CA).

Recombinant Vaccinia Viruses.
-----------------------------

The minigene recombinant vaccinia were constructed using synthetic oligonucleotides (5′ GTACCACCATGTATATGAATGGAACAATGTCCCAGGTATA 3′ and 5′ AGCTTATACCTGGGACATTGTTCCATTCATATACATGGTG 3′ for peptide (M)YM**[N]{.ul}**GTMSQV and 5′ GTACCACCATGTATATGGATGGAACAATGTCCCAGGTATA 3′ and 5′ AGCTTATACCTGGGACATTGTTCCATCCATATACATGGTG 3′ for peptide (M)YM**[D]{.ul}**GTMSQV) ligated directionally into the plasmid pSC11.3 ([@B54]) at the Acc65I and HindIII sites. In addition to appropriate overhang sequences for ligation, the synthetic nucleotide sequences contained a favorable Kozac sequence for translation initiation, a methionine start codon, the nucleotides encoding the T cell epitope, and a translational stop signal. The full-length tyrosinase was excised from the pcDNA1/amp-123.b2 vector using HindIII and XbaI and subcloned into pSC11.3 at the HindIII and SpeI sites. Recombinant vaccinia viruses were produced from these vectors using standard methods ([@B55]). Purified vaccinia stocks were titered and tested for proper expression of tyrosinase or minigene using specific murine HLA-A2--restricted CTL. Vaccinia viruses encoding the TAP1 and TAP2 genes were a gift from Drs. Jon Yewdell and Jack Bennink (Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, MD).

CTL Lines and Cytotoxicity.
---------------------------

CTL lines were generated by intraperitoneal injection of 5 × 10^8^ PFUs of recombinant vaccinia encoding either YM**[D]{.ul}**GTMSQV or YM**[N]{.ul}**GTMSQV into C57Bl/6 mice expressing a chimeric MHC class I with the α1 and α2 domains from HLA-A2.1 and the α3 domain from K^d^ ([@B56]). 3 wk after priming, splenocytes were removed and stimulated with autologous, irradiated splenocytes that had been pulsed with YM**[D]{.ul}**GTMSQV or YM**[N]{.ul}**GTMSQV peptide. After the first week in culture, autologous, irradiated peptide-pulsed splenocytes and 10 U/ml IL-2 were added. IL-2 was also added on day 4 of every weekly stimulation. Standard ^51^Cr-release assays were performed to determine CTL recognition of tyrosinase peptides. For peptide dose response assays, T2 cells were ^51^Cr-labeled in the presence of 10 μg/ml MA2.1. and then incubated with the indicated concentrations of synthetic tyrosinase peptides for 3 h at 37°C. For vaccinia-infected target cells, 2 × 10^7^ PFUs vaccinia were added to 10^6^ targets in HBSS for 1 h. RPMI with 10% FCS, 15 mM Hepes, 50 μM β-mercaptoethanol, 2 mM glutamine, and essential and nonessential amino acids was then added to the infected cells for 9 h to allow for expression. Targets were labeled in 100 μCi Na^51^CrO~4~ for the final 2 h. CTLs were added at an effector: target ratio of 10:1 unless otherwise noted.

HLA-A\*0201-associated Peptide Isolation.
-----------------------------------------

Peptides were acid eluted from affinity-purified HLA-A\*0201 molecules as previously described ([@B49], [@B57]). The peptide extracts from 2 × 10^9^ NA8 Mel + Tyr or 3 × 10^9^ NA8 Mel + T3.1 cells were separated on a narrow bore reverse phase column (RP-18 Spheri-5, 2.1 × 3 mm). Buffer A was 0.1% TFA in water and buffer B was 0.085% TFA in 80% acetonitrile. The gradient consisted of 100% buffer A (0--20 min), 0--15% buffer B (20--25 min) and 15--67% buffer B (25--80 min) at a flow rate of 200 μl/min. The synthetic peptides YM**[D]{.ul}**GTMSQV and YM**[N]{.ul}**GTMSQV were separated on the same column under identical conditions immediately after the extracts, and their elution positions were used to identify fractions from the extracts that contained the naturally processed forms of these peptides. These fractions were loaded onto a C18 microcapillary column (75 μm intradermally × 12 cm) and eluted using a 2%/min increasing gradient of acetonitrile in 0.1 M acetic acid into a triple quadropole mass spectrometer (model TSQ-7000; Finnigan) equipped with an electrospray ion source. Scans were acquired every 1.5 s over a mass range m/z (mass/charge ratio) 300:1400 and then plotted with intensities for m/z 1,031: 1,032. For the NA8 Mel + Tyr peptide extract, 10% of the sample was analyzed by mass spectrometry. For the NA8 Mel + T3.1 peptide extract, 20% of the sample was analyzed by mass spectrometry. The loaded sample amounts were standardized using an unrelated peptide of m/z 541 found in fractions 28, 29, and 30. We determined the cell surface copy numbers of YM**[D]{.ul}**GTMSQV peptides using synthetic YM**[D]{.ul}**GTMSQV peptides as standards.

Inhibitors.
-----------

Lactacystin (gift of Dr. S. Omura of the Kitasato Institute, Tokyo, Japan) is a *Streptomyces* metabolite which irreversibly inhibits proteasomes via covalent binding to the active sites of the catalytically active β subunits ([@B58]). LLnL, also known as Calpain Inhibitor I, was purchased from Calbiochem (La Jolla, CA). LLnL reversibly inhibits proteasomes as well as several other classes of proteases, including cysteine proteases, calpain, and cathepsin B ([@B59]).

Epitope Reexpression Assay.
---------------------------

Tumor targets (1--2 × 10^7^) were grown in RPMI 1640 supplemented with 5% FCS/SerXtend and then centrifuged. The pellet was gently resuspended in 500 μl of 300 mM glycine, pH 2.5, 1% (wt/vol) BSA and incubated for 3 min at 37°C. The suspension was diluted with 40 ml of RPMI 1640 medium supplemented with 5% FCS/SerXtend and then centrifuged. Cells (2 × 10^6^) were aliquoted into 1 ml of RPMI 1640 medium supplemented with 5% FCS/SerXtend and 100 μCi Na ^51^CrO~4~ in the presence or absence of 10 μg/ml of Brefeldin A (BFA), 10 μM Lactacystin, or 250 μM LLnL, and incubated at 37°C to allow epitope reexpression for 5 h. After washing four times, all targets were resuspended in RPMI 1640 medium supplemented with 5% FCS/SerXtend and 10 μg/ml BFA to inhibit further epitope expression, and used in a standard 4-h ^51^Cr-release assay.

Cell Fractionation.
-------------------

10^7^ NA8 Mel and DM93 melanoma cells were frozen twice in liquid N~2~ and thawed in 1 ml of hypoosmotic lysis buffer consisting of 20 mM Hepes, 2 mM EDTA, and a protease inhibitor cocktail containing 4 mM PMSF, 10 μg/ml aprotinin, 10 μM pepstatin A, 10 μg/ml leupeptin, and 100 μM iodoacetamide. The lysate was centrifuged at 16,000 *g* at 4°C for 15 min. The supernatant was collected as the cytosolic fraction. The pellet was washed twice with the hypoosmotic lysis buffer before being solubilized in 1 ml of 0.5% deoxycholate, 1% NP-40, 5 mM EDTA, 10 mM Tris, pH 7.5, and the protease inhibitor cocktail described earlier. This lysate was spun at 16,000 *g* for 15 min at 4°C. The supernatant was collected as the membrane fraction. Whole cell lysate was obtained using 1 ml of the 0.5% deoxycholate, and 1% NP-40 lysis buffer for 10^7^ cells. The suspension was incubated for 1 h at 4°C and spun at 30,000 *g* for 30 min at 4°C, and then the supernatant was collected. As a control to determine the separation efficiency of the membrane and cytosolic fractions, each fraction was immunoblotted for TAP, which was only present in the membrane fraction (data not shown).

Immunoblotting.
---------------

10^6^ cell equivalents per lane were separated by SDS-PAGE ([@B60]) on 10% gels. Gels were transferred to Immobilon P and blocked with 5% nonfat dried milk in PBS with 0.05% Tween 20. Blots were probed with either the antityrosinase mAb T311 (61; gift from Drs. E. Stockert and L. Old, Ludwig Institute for Cancer Research, Memorial Sloan Kettering, New York), at a 1:10 dilution of culture supernatant, or the anti-TAP mAb (gift from Robert Tampe, Max-Planck-Institute, Martinsried, Germany), at a 1:30 dilution. After 10 h, blots were washed and probed with horseradish peroxidase--conjugated sheep anti--mouse IgG, and developed according to the Amersham ECL protocol (Amersham Corp., Arlington Heights, IL).

Deglycosylation of Tyrosinase.
------------------------------

Membrane or cytosolic fractions from 5 × 10^5^ cells generated as described above were precipitated via the addition of 8 volumes of acetone and incubating at −20°C for 3 h. The precipitate was resuspended in 25 μl 0.5% SDS/0.1 M β-mercaptoethanol and boiled for 5 min. After cooling to room temperature, 25 μl sodium phosphate, pH 7.0, 10 μl 1,10 phenanthroline, 10 μl 10% NP-40, and 5 μl of PNGase F 300 mU/ml (Sigma Chemical Co., St. Louis, MO) were added, and the reactions were incubated for the indicated times at 37°C.

Results {#Results}
=======

To detect either the YM**[D]{.ul}**GTMSQV or the YM**[N]{.ul}**GTMSQV epitopes, we developed CTLs specific for each peptide from transgenic mice expressing a chimeric HLA-A\*0201/H2D^d^ molecule. CTLs generated against the YM**[D]{.ul}**GTMSQV peptide (D-specific CTLs) required 5--6 logs less of the YM**[D]{.ul}**GTMSQV peptide than the YM**[N]{.ul}**GTMSQV peptide to give equivalent lysis of peptide-pulsed target cells (Fig. [1](#F1){ref-type="fig"} *A*). Conversely, CTLs generated against the YM**[N]{.ul}**GTMSQV peptide (N-specific CTLs) required 5--6 logs less YM**[N]{.ul}**GTMSQV than YM**[D]{.ul}**GTMSQV for recognition (Fig. [1](#F1){ref-type="fig"} *B*). Since YM**[N]{.ul}**GTMSQV and YM**[D]{.ul}**GTMSQV bind to HLA-A2.1 with similar affinities ([@B49]), these differences reflect the ability of the CTLs to discriminate between these two peptides. Nevertheless, HLA-A\*0201^+^ melanomas expressing tyrosinase were lysed by D-specific CTLs but not by N-specific CTLs at similar effector:target ratios (Fig. [2](#F2){ref-type="fig"}). The lack of reactivity of N-specific CTLs with these tumors confirms our earlier conclusion based on mass spectrometry data ([@B49]) that there is no YM**[N]{.ul}**GTMSQV peptide on the cell surface, although the tyrosinase gene encodes this sequence.

One possible explanation for the lack of expression of the unconverted YM**[N]{.ul}**GTMSQV peptide on the surface of melanoma cells was that it was not transported via TAP after production in the cytosol. Androlewicz ([@B62]) recently demonstrated that this peptide was transported in an in vitro system. We used a recombinant vaccinia virus expressing a minigene encoding YM**[N]{.ul}**GTMSQV to address this question in vivo. HLA-A\*0201^+^ lymphoblastoid JY cells infected with this vaccinia construct were lysed by N-specific CTL but not D-specific CTL (Fig. [3](#F3){ref-type="fig"}). These results demonstrate that the YM**[N]{.ul}**GTMSQV peptide produced in the cytosol can be expressed in association with HLA-A\*0201 molecules at the cell surface. In addition, this expression is dependent upon the expression of TAP by the target cell (data not shown). Interestingly, however, expression of this minigene-encoded form of the YM**[N]{.ul}**GTMSQV sequence did not result in conversion and presentation of the YM**[D]{.ul}**GTMSQV peptide at the surface. This contrasts to the presentation of only the YM**[D]{.ul}**GTMSQV peptide in cells expressing full-length tyrosinase.

One explanation for the exclusive production of YM**[D]{.ul}**GTMSQV from full-length tyrosinase and of YMN from the minigene is that the former is translated in the ER, where it undergoes conversion, whereas the latter is translated in the cytosol, where it does not. However, the minigene product was preprocessed to the ideal length to bind to HLA-A\*0201, while the full-length tyrosinase requires proteolysis before binding. Therefore, it was also possible that immediate binding of the minigene product to HLA-A\*0201 after entry into the ER prevented conversion, whereas longer peptides derived from full-length tyrosinase were converted before being trimmed to the optimal length for binding. To distinguish between these two possibilities, we transfected NA8 Mel, a tyrosinase-negative melanoma cell line, with a truncated tyrosinase gene fragment called T3.1 ([@B51]). The translation product of T3.1 spans residues 143--377 of the full-length tyrosinase sequence (Fig. [4](#F4){ref-type="fig"}). Because it lacks the NH~2~-terminal end of full-length tyrosinase, including the signal sequence, it should be translated in the cytosol, as is the minigene, rather than the ER. However, the YM**[N]{.ul}**GTMSQV epitope sequence in T3.1 (residues 368--376) is bounded by 225 residues at its NH~2~ terminus and 1 residue at its COOH terminus. To be presented by HLA-A\*0201, it requires additional processing as compared to the minigene product. If the failure of the minigene product to undergo conversion were due to its expression in the cytosol, regardless of length, then we would expect that cells expressing T3.1 would also express the unconverted peptide epitope. This was found to be the case (Fig. [5](#F5){ref-type="fig"} *A*). We conclude from this that the production of the unconverted epitope is associated with translation in the cytosol, and that its absence from cells expressing full-length tyrosinase indicates that the converted epitope is produced from this protein after it is translated into the ER, rather than mistranslated in the cytosol. Although the presence of the unconverted epitope was clearly associated with the translation of protein in the cytosol, the absence of the converted epitope was not. Surprisingly, we found that cells expressing T3.1 presented the converted epitope as well as the unconverted form (Fig. [5](#F5){ref-type="fig"} *B*). This low but reproducible level of lysis by the D-specific CTL indicates that cytosolic proteins can give rise to epitopes that have undergone conversion.

One possible caveat to the conclusion that the presence of the unconverted epitope was associated with cytosolic translation was the possibility that the amount of T3.1 protein in the cells, or its inability to fold appropriately, led to the accumulation of a much higher level of the YM**[N]{.ul}**GTMSQV peptide or a precursor than would be produced in cells expressing full-length tyrosinase. This could lead to a saturation of the processing and conversion machinery, resulting in a failure to convert all of the peptides produced in the T3.1 transfectant to YM**D**GTMSQV. However, if this were so, then the T3.1 transfectant should express an amount of the converted YM**D**GTMSQV peptide equal to or higher than that found on the full-length transfectant. Consequently, we immunoaffinity purified the HLA-A2.1 molecules from comparable amounts of NA8 Mel + T3.1 and NA8 Mel + Tyr, and extracted the associated peptides. After HPLC separation, we used tandem mass spectrometry to determine the quantity of the YM**D**GTMSQV peptide in these extracts (Fig. [6](#F6){ref-type="fig"}). A coeluting species at m/z 541 was found in both extracts and was used to normalize the amount of cell extract injected into the mass spectrometer. By using known amounts of synthetic peptide as a standard, we determined the quantity of this peptide in each extract, and normalized to the number of cell equivalents of material injected. The density of YM**[D]{.ul}**GTMSQV on the full-length tyrosinase transfectant was determined to be 1,400 peptides per cell, in good agreement with a previously reported value of 1,200 copies per cell ([@B49]). However, the density of this peptide on the T3.1 transfectant was only 50 copies per cell, or 4% of that seen on the NA8 + Tyr cells. Although detected by N-specific CTL, the density of YM**[N]{.ul}**GTMSQV on the NA8 Mel + T3.1 transfectant was too low to be detected by mass spectrometry with the amount of cell extract analyzed (\<25 copies per cell). These results demonstrate that the T3.1 transfectant generated less YM**[D]{.ul}**GTMSQV than did the full-length tyrosinase transfectant, and indicate that the presence of the unconverted peptide in the T3.1 transfectant was not due to saturation of the processing and conversion machinery. We conclude that the processing of the T3.1 translation product and full-length tyrosinase must differ in some respect. Since T3.1 has no signal sequence or transmembrane domain, it should be produced in the cytosol and processed by the classical antigen-processing pathway. Since full-length tyrosinase does not give rise to the unconverted peptide that is characteristic of cytosolic translation of both T3.1 and the minigene, it must therefore be translated in the ER, and undergo processing in a distinct manner.

Several epitopes from membrane proteins are generated by a pathway that is independent of the TAP protein, suggesting that after translation in the ER, their processing can be completed in this compartment ([@B37], [@B63]--[@B65]). We were interested in whether the formation of YM**[D]{.ul}**GTMSQV from full-length tyrosinase, which involves both translation in the ER and conversion at an unknown site, was also TAP-independent. T2 cells, which are HLA-A\*0201^+^ but have deleted the genes encoding TAP1 and TAP2, were infected with a vaccinia vector encoding full-length tyrosinase and screened with the D-specific CTLs. There was no lysis of the vaccinia-tyrosinase--infected T2 cells. However, when T2 cells were infected with a mixture of recombinant vaccinia viruses expressing tyrosinase and the genes encoding TAP1 and TAP2, the YM**[D]{.ul}**GTMSQV epitope was restored on the cell surface (Fig. [7](#F7){ref-type="fig"}). These results demonstrate that the production of the YM**[D]{.ul}**GTMSQV epitope is TAP-dependent, and indicates that it, or a precursor that contains the epitope, is in the cytosol before binding HLA-A2.1 in the ER.

Because of the TAP dependence of the YM**[D]{.ul}**GTMSQV epitope, we were interested in determining whether the proteasome is involved in epitope formation. Proteasome-dependent processing was evaluated by brief exposure of target cells to pH 2.5 medium to denature all cell surface MHC class I molecules, followed by incubation to allow reexpression of the epitope in the presence or absence of lactacystin or LLnL as described elsewhere (Luckey, C.J., G.M. King, J.A. Marto, B.F. Maier, V.L. Crotzer, T.A. Colella, J. Shabanowitz, D.F. Hunt, and V.H. Engelhard, manuscript submitted for publication). CTL recognition of acid-treated target cells was abolished, but recovered to control levels if the targets were incubated for 5 h at 37°C (Fig. [8](#F8){ref-type="fig"}). This recovery of epitope expression was inhibited by \>50% in the presence of BFA, which blocks the egress of newly synthesized peptide MHC class I complexes from the ER ([@B66]--[@B68]). Although the failure of BFA to completely inhibit reexpression of the epitope is not understood, the difference in recognition between the acid-washed, untreated cells and the acid-washed, BFA-treated cells allowed us to determine whether protease inhibitors also blocked the generation of the YM**[D]{.ul}**GTMSQV epitope. Incubation of acid-washed targets with 20 μM LLnL, a concentration known to selectively inhibit the proteasome ([@B59]), inhibited reexpression of the YM**[D]{.ul}**GTMSQV epitope on the cell surface to the same extent as BFA (Fig. [8](#F8){ref-type="fig"}). In addition, treatment of the acid-washed cells with lactacystin, a highly specific inhibitor of the proteasome ([@B58]), also blocked reexpression of the YM**[D]{.ul}**GTMSQV epitope. It has been shown elsewhere that the effects of these proteasome inhibitors are not due to nonspecific effects on class I biosynthesis or susceptibility of target cells to CTL-mediated lysis (Luckey, C.M.J., G.M. King, J.A. Marto, B.F. Maier, V.L. Crotzer, T.A. Colella, J. Shabanowitz, D.F. Hunt, and V.H. Engelhard, manuscript submitted for publication). Together these results indicate that the processing of intact tyrosinase to generate the YM**D**GTMSQV epitope is dependent upon the proteasome.

The results obtained thus far suggested that initial translation of tyrosinase in the ER was followed by the export of the full-length protein or a fragment to the cytosol for processing by the proteasome. To investigate the nature of the tyrosinase species exported from the ER to the cytosol, we used lactacystin to inhibit proteasome activity in DM93, a tyrosinase-expressing melanoma, and NA8 Mel, a tyrosinase-negative melanoma. After 5 h the cells were divided into cytosolic and membrane fractions, separated by SDS-PAGE, and immunoblotted for tyrosinase (Fig. [9](#F9){ref-type="fig"}). In untreated DM93 cells, we observed a strong doublet of 70--75 kD that was located exclusively in the membrane fraction. This doublet represents two major glycosylated species of tyrosinase, and correlate well with those previously identified by others ([@B61], [@B69]). In DM93 cells that had been treated with lactacystin, three additional bands were observed at 56--58 kD, similar in size to the unglycosylated full-length tyrosinase. The band of lowest mobility among this group was located exclusively in the membrane fraction, whereas the other two were found only in the cytosol. To further identify the potential nature of these lower molecular weight bands, the membrane fraction from DM93 cells was treated with PNGase F to deglycosylate asparagine-linked glycosylations (Fig. [10](#F10){ref-type="fig"}). Human tyrosinase contains seven potential glycosylation sites ([@B70], [@B71]) yet it appears that only four or five sites are used in DM93 cells. Although deglycosylation was not complete after 12 h, the fastest migrating species comigrated with the cytosolic 57-kD band, which appears after lactacystin treatment of DM93 cells. One additional species with an apparent molecular weight of 85-kD was found in the cytosol of untreated cells, but increased in intensity upon lactacystin treatment. The size of this band is too high to be attributed to glycosylation, but is consistent with the attachment of four ubiquitin chains to the unglycosylated full-length tyrosinase polypeptide chain. After long exposure times, two additional low intensity bands of 61 and 65 kD were also found in the cytosol. None of these bands were observed in extracts of NA8 Mel (Fig. [9](#F9){ref-type="fig"}), whereas a similar pattern was observed in NA8 Mel + Tyr cells (data not shown), indicating that all of the species are derived from tyrosinase. These results are consistent with the hypothesis that the export of a full-length or almost full-length tyrosinase from the ER for degradation by the proteasome provides source material for the production of the YM**[D]{.ul}**GTMSQV peptide epitope.

Discussion {#Discussion}
==========

In a previous paper, we demonstrated that the peptide YM**[D]{.ul}**GTMSQV is formed by the processing and post-translational modification of the sequence YM**[N]{.ul}**GTMSQV located in the full-length tyrosinase protein sequence ([@B49]). Since the proposed posttranslational modification responsible for this conversion involved glycosylation in the endoplasmic reticulum, and since tyrosinase is a membrane protein, the objective of this study was to determine whether processing to produce this epitope occurred after normal translation of tyrosinase into the endoplasmic reticulum, or after aberrant translation in the cytosol. Using either a vaccinia-encoded minigene or a transfected fragment of tyrosinase that is missing the signal sequence, we have demonstrated that translation of the sequence YM**[N]{.ul}**GTMSQV in the cytosol results in detectable quantities of this unconverted peptide on the cell surface in association with HLA-A\*0201. In contrast, this peptide is not observed in cells that express the full-length form of tyrosinase. This suggests that the routes by which the full-length and truncated protein forms are processed are different, and that the full-length form is not processed after mistranslation in the cytosol.

It is not immediately clear why expression of the unconverted YM**[N]{.ul}**GTMSQV peptide should be a marker of protein translation in the cytosol. It is also unclear why this is the only form detectable on the surface of cells expressing the peptide epitope as a vaccinia minigene, whereas in cells expressing the T3.1 fragment of tyrosinase, both this and the posttranslationally converted epitopes are detected. We believe that the most likely explanation lies in the length and heterogeneity of the epitope-containing fragments produced from these two translation products. The vaccinia minigene product contains the unconverted YM**[N]{.ul}**GTMSQV peptide in "preprocessed" form with the exception of an NH~2~-terminal methionine residue that is likely to be rapidly removed by cytosolic aminopeptidases ([@B72]). As a result, the epitope-containing peptides that are located in the cytosol and transported into the ER by TAP are of the optimal size to bind to newly synthesized HLA-A\*0201 molecules. Androlewicz has demonstrated TAP-dependent transport of the YM**[N]{.ul}**GTMSQV peptide from the cytosol to the ER, and has further shown that a fraction of these HLA-A\*0201--associated peptides become glycosylated ([@B62]). However, we hypothesize that rapid peptide binding prevents further posttranslational conversion of asparagine to aspartic acid by deglycosylation or another mechanism, either because of steric hindrance or because trafficking of class I--peptide complexes does not bring them into contact with all of the enzymes necessary to mediate this process. As a result, the converted form of the peptide is not expressed at the cell surface.

In contrast, the epitope-containing fragments produced after translation and the initial processing of the T3.1 protein could contain an additional COOH-terminal residue and up to 225 additional residues at the NH~2~ terminus. Based on the size selectivity of TAP ([@B73]), it is likely that only those epitope-containing peptides of 9--16 amino acids will be efficiently transported into the ER. As with the minigene-encoded peptides, those 9mers with the sequence YM**[N]{.ul}**GTMSQV would immediately bind to HLA-A\*0201 and be protected from posttranslational conversion. However, those peptides of 10--16 residues would be unable to bind to HLA-A\*0201 because the dominant motif residues are no longer positioned appropriately with respect to the peptide termini. These peptides would be substrates for enzymes that mediate the conversion of asparagine to aspartic acid. After additional proteolytic processing, they would give rise to the YM**[D]{.ul}**GTMSQV peptides associated with HLA-A\*0201.

Regardless of whether the above hypothesis is correct in all aspects, the absence of the unconverted peptide and the exclusive presence of the posttranslationally converted form in cells expressing full-length tyrosinase indicates that the unconverted 9mer peptide is not produced at all, or at least is not produced in a compartment that allows it to bind to HLA-A\*0201 before conversion. One possibility is that the normal translation of full-length tyrosinase in the ER results in quantitative glycosylation of the asparagine residue in the context of the intact protein, thus precluding the possibility of producing the unconverted peptide. Deglycosylation before, after, or during proteolysis would lead to conversion of asparagine to aspartic acid, and result in the production of the converted YM**[D]{.ul}**GTMSQV peptide. Alternatively, if glycosylation is incomplete, the unconverted N residue may be a site for proteolysis in the ER, resulting in epitope destruction. In this scenario, the production of the unconverted peptide from T3.1 would be a result of incomplete glycosylation or incomplete proteolysis in the ER, presumably as a result of association with HLA-A\*0201. Thus, the differential expression of unconverted and converted forms of this tyrosinase-derived peptide is most likely to be due to the site of translation, the extent of glycosylation, the length of the fragments produced during initial proteolytic processing, and protection from further processing by association with HLA-A\*0201.

Given the initial translation of full-length tyrosinase in the ER, a second important result of this study is that the expression of the converted peptide epitope in association with HLA-A\*0201 is dependent on TAP and the proteasome. Although it was formally possible that this peptide is fully processed in the ER, and that the role of TAP was to enable efficient peptide loading by interaction with an HLA-A\*0201--tapasin complex ([@B64]), the inhibition of epitope formation by the specific proteasomal inhibitor lactacystin provides strong evidence that processing occurs at least in part in the cytosol. In fact, in the presence of this inhibitor, tyrosinase species of molecular weights that were consistent with a full-length deglycosylated polypeptide chain were detected in the cytosol. These results are consistent with observations in several other laboratories of a reverse translocation mechanism for the export of misfolded membrane proteins from the ER for degradation by the proteasome ([@B37]--[@B48]). In addition, tyrosinase expressed in amelanotic melanomas was recently shown to be trapped in the ER and then degraded by a lactacystin-dependent pathway ([@B74]). Our results do not allow us to completely exclude a mechanism in which tyrosinase is partially degraded by proteases in the ER, followed by export of the fragments to the cytosol for processing by the proteasome. Nonetheless, we believe that the most likely mechanism involves the reverse translocation of the full-length protein into the cytosol, accompanied by deglycosylation, and followed by proteasomal processing. Previous studies have provided suggestive evidence for two mechanisms of membrane protein processing that involve partial or complete proteolysis in the ER ([@B11]--[@B20]), or mistranslation of the protein in the cytosol (21--25, 27-- 35). The results of this study provide strong evidence for a third pathway that involves reverse translocation of the intact protein from the ER to the cytosol for proteolysis. If, as seems likely, this is a normal pathway for the degradation of misfolded membrane and secreted proteins, then we think it likely that it will also be the major pathway for processing and presentation of the epitopes from these proteins as well.
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*Abbreviations used in this paper:* BFA, brefeldin A; ER, endoplasmic reticulum; m/z, mass/charge ratio; TAP, the transporter associated with antigen.

![Recognition of tyrosinase-derived peptides by D-specific and N-specific CTLs. Indicated concentrations of YM**[D]{.ul}**GTMSQV (*squares*) or YM**[N]{.ul}**GTMSQV (*triangles*) were incubated with ^51^Cr-labeled T2 cells in the presence of 10 μg/ml MA2.1 Ab for 3 h at 37°C. D-specific (*A*) or N specific (*B*) CTL were added at an E:T ratio of 10:1 for a 4-h ^51^Cr-release assay.](JEM.970377f1){#F1}

![Recognition of melanoma tumor lines by D-specific CTLs (*solid symbols*) and N-specific CTLs (*open symbols*) in a 4-h ^51^Cr-release assay. DM6 (*circles*), DM93 (*squares*), and NA8 Mel + Tyr (*triangles*) express full-length tyrosinase while NA8 Mel (*crosses*) does not.](JEM.970377f2){#F2}

![Recognition of JY cells infected with various vaccinia-encoded minigene constructs. JY cells were incubated with no vaccinia (*white bars*), an irrelevant vaccinia control encoding YLEPGPVTA (*gray bars*), D minigene vaccinia encoding YM**[D]{.ul}**GTMSQV (*black bars*), or N minigene vaccinia encoding YM**[N]{.ul}**GTMSQV (*striped bars*).](JEM.970377f3){#F3}

![Schematic of tyrosinase peptide encoding constructs.](JEM.970377f4){#F4}

![Recognition of NA8 Mel and transfectants by N-specific (*A*) and D-specific (*B*) CTLs in a 4-h ^51^Cr-release assay. Targets used were the tyrosinase negative melanoma NA8 Mel (*circles*), its full-length tyrosinase transfectant NA8 Mel + Tyr (*squares*), or its T3.1 transfectant NA8 Mel + T3.1 (*triangles*). The results are representative of five independent experiments.](JEM.970377f5){#F5}

![Ion chromatograms recorded on peptides from fractions 28-- 30 of the first dimension separation of NA8 Mel + Tyr (*A*) and NA8 Mel + T3.1 (*B*) extracts. Sample preparation and mass spectrometric analysis are described in Materials and Methods. After mass spectra were acquired, a computer search was conducted to determine the abundance of ions in a 2-mass unit window centered on either m/z 1032, which corresponds to the (M+H)^+^ ion species of YM**[D]{.ul}**GTMSQV or m/z 541, an unknown peptide which was found in these pooled fractions in both extracts. The 541 peptide was used to normalize the number of cell equivalents loaded onto the mass spectrometer for each sample.](JEM.970377f6){#F6}

![TAP dependence of YM**[D]{.ul}**GTMSQV epitope formation. T2 cells were infected with recombinant vaccinia viruses expressing either tyrosinase (*squares*), TAP1+2 (*triangles*), or both tyrosinase and TAP1+2 (*closed circles*), or else left uninfected (*open circles*), and used in a ^51^Cr-release assay with D-specific CTLs. The results are representative of three independent experiments.](JEM.970377f7){#F7}

![Recognition of the melanoma line DM93 by D Tyr CTL. DM93 was left untreated (*crosses*) or acid-treated as described in Materials and Methods and then incubated at 37°C for 5 h either in the absence of any inhibitor (*diamonds*) or in the presence of one of the follwing: 10 μg/ml BFA (*squares*), 20 μM lactacystin (*triangles*) or 20 μM LLnL (*circles*). All targets were then washed and used in a 4-h ^51^Cr-release assay in the presence of 10 μg/ml BFA to block any further expression of newly synthesized peptide--HLA-A\*0201 complexes. These results are representative of four independent experiments.](JEM.970377f8){#F8}

![Tyrosinase can be detected in the cytosol of lactacystin treated melanoma. NA8 Mel (lanes *1--6*), a tyrosinase-negative melanoma, and DM93 (lanes *7--12*), a tyrosinase-expressing melanoma, were left untreated (lanes *1--3*, *7--9*) or treated (lanes *4--6*, *10--12*) with 10 μg/ml lactacystin for 5 h, after which time they were separated into membrane (lanes *1*, *4*, *7*, *10*) or cytosolic (lanes *2*, *5*, *8*, *11*) fractions or used as whole cell lysates (lanes *3*, *6*, *9*, *12*) as described in Materials and Methods. Lysate equivalent to 10^6^ cells was run in each lane of a 10% SDS-PAGE denaturing gel. The blot from this gel was probed with T311, a tyrosinase specific mAb. These results are representative of four independent experiments.](JEM.970377f9){#F9}

![Deglycosylation of membrane tyrosinase produces a band which comigrates or nearly comigrates with the tyrosinase species found in the cytosol. Lane *1* contains the membrane fraction from 5 × 10^5^ cells mock treated with PNGase F. Lanes *2--5* contain equivalent DM93 membrane fractions treated with 1.5 mU PNGase for 2, 4, 8 and 12 h, respectively. Lane *6* contains the cytosolic fraction of 5 × 10^5^ DM93 cells treated with lactacystin for 5 h.](JEM.970377f10){#F10}
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